Trial
NCT01737827
Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Advanced Hepatocellular Carcinoma With c-MET Dysregulation
Intervention
INC280
Why stopped
The study recruitment was ended due to difficulties in identifying subjects who meet the eligibility criteria and therefore the study never reached its planned sample size per protocol. The study termination was not due to any safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-24